🇺🇸 FDA
Patent

US 11236161

Chimeric antigen receptors targeting CD-19

granted A61KA61K2239/13A61K2239/31

Quick answer

US patent 11236161 (Chimeric antigen receptors targeting CD-19) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2239/13, A61K2239/31, A61K2239/48, A61K40/11